Sales survey of Veterinary Medicinal Products containing Antimicrobials in France

Size: px
Start display at page:

Download "Sales survey of Veterinary Medicinal Products containing Antimicrobials in France"

Transcription

1 Sales survey of Veterinary Medicinal Products containing Antimicrobials in France February 2011 Édition scientifique

2 Sales survey of Veterinary Medicinal Products containing Antimicrobials in France February 2011 Édition scientifique The French Agency for Veterinary Medicinal Products La Haute Marche - Javené - BP F Fougères Cedex - France

3 National agency for veterinary Medicinal products Sales survey of Veterinary Medicinal Products containing Antimicrobials in France Fougères, February 2011 G. Moulin and A. Chevance, Anses-ANMV With the participation of Claire Chauvin, Anses-Ploufragan

4 Summary The French monitoring system of veterinary antimicrobials was initiated in It is coordinated by the French Agency for Veterinary Medicinal Products (Anses/ANMV), in collaboration with the French Veterinary Medicine Industry association (SIMV), and is performed according to the OIE guideline on monitoring of antimicrobials (in Animal Terrestrial Code 2009 Chapter 6.8). The monitoring is based on a questionnaire sent to each applicant who has registered a veterinary medicinal product containing antimicrobials. In 2009, the applicants were required to provide information about the repartition between species for each commercial presentation in addition to the number of sold units. Sales in weight of active ingredients In 2009, the total sales volume accounts for tons of antimicrobials. As for previous years, four antimicrobial classes (Tetracyclines, Sulfonamides, Penicillins, Macrolides) represent more than 80 % of the tonnage of sold antimicrobials. Tetracyclines alone represent around half of the overall. Fluroquinolones and Cephalosporins volumes are relatively low. In 2009, the total antimicrobial sales have decreased of 13 % (159 tons) compared to 2008 and the sales have decreased of 19.3 % (255 tons) compared to The 2009 sales represent the lowest sales volume recorded during the 11 years period. This decrease is mainly due to the sales of antimicrobials belonging to Tetracyclines (decrease of 22.2 % i.e. 139 tons) and to Sulfonamides (decrease of 32.0 % i.e. 86 tons). Compared to 1999, the sales of Fluoroquinolones have increased of % (i.e tons) and the sales of Quinolones have decreased of 63.3 % (i.e tons). Compared to 2008, the sales of Fluoroquinolones have stabilized in 2009 (+0.09 %) Compared to 1999, the sales of 3 rd and 4 th generation Cephalosporins have increased of % (i.e ton) and the sales of 1 st and 2 nd generation Cephalosporins have increased of 28.4 % (i.e. 1,5 tons). Compared to 2008, the sales of 3 rd and 4 th generation Cephalosporins have decreased of 13.7 % (i.e ton). Sales in weight of active ingredients per Kg of animal bodyweight When taking into account the weight of animals treated, the decrease is only of % compared to In 2009, sales correspond to an equivalent of mg/kg of animal weight produced. The sold tonnages per class do not represent accurately the use of antimicrobials as differences in dosages and durations of administration are not taken into account. Antimicrobials belonging to the new classes generally require a lower weight of active ingredient to treat one animal than an old antimicrobial. 1

5 Weight of animal treated with antimicrobials To evaluate the exposure to antimicrobials, the weight of animal treated has been evaluated for each substance administrated orally and parenterally. For the intra-mammary route, the number of treatments for each medicinal product has been calculated. The weight of animals treated by parenteral route decreases of 14.6 % in 2009 compared to The weight of animals treated by oral route increases of 12.8 % in 2009 compared to However, a decrease is noticed for the 2 last years (a decrease of 14.4 % in 2009 compared to 2007). The number of animals treated by intra-mammary route decreases of 15.4 % compared to 2008 and of 28.7 % compared to Exposure to antimicrobials The antimicrobial exposure index (ALEA: Animal Level of Exposure to Antimicrobials) is obtained by dividing the weight of animal treated by the weight of the animal population potentially treated. The ALEA index is an estimate that is strongly correlated to the number of animal treated in the population and is a good output to evaluate the exposure to antimicrobials. When comparing 2009 and 1999 results, the ALEA index representing the exposure to antimicrobials (for the oral and parenteral routes), irrespective of classes and species, increases of 12.6 %. Compared to 2008, the ALEA index decreases of 3.9 %. The evolution on the last two years shows a change in the trend observed until 2007, this reduction of the exposure has to be confirmed the next years. 0,900 0,800 0,700 0,600 0,500 0,400 0,300 0,200 0,100 0,000 Evolution of the exposure to antimicrobials Oral and parenteral routes (ALEA) Oral route (including premixes) Premixes Parenteral route Total (oral and parenteral routes) Between 1999 and 2009, 16 new marketing authorizations of veterinary medicine products with Fluoroquinolones have been granted (18 in 1999 vs. 34 in 2009), over this same time, 2

6 the level of exposure has increased of 93.6 % for Fluoroquinolones and has decreased of 53.8 % for Quinolones. Compared to 2008, the level of exposure to Fluoroquinolones has decreased of 0.85 %. Compared to 1999, the number of marketing authorizations of veterinary medicine products with 3 rd and 4 th generation Cephalosporins has doubled (6 in 1999 vs. 12 in 2009). Over this same time, the level of exposure to 3 rd and 4 th generation Cephalosporins has increased of % and the level of exposure to 1 st and 2 nd generation Cephalosporins has increased of 43.8 %. Compared to 2008, the level of exposure to 3 rd & 4 th generation Cephalosporins has decreased of 14.8 %. Discussion The methodology implemented in this antimicrobials sales survey does not allow to describe with precision the off label use, even if the new approach implemented in 2009 (estimate of the repartition between species by MA holders) takes partly into account this type of use. Complementary field studies have been or should be performed in order to complement the information obtained with this national antimicrobials sales survey. The important decrease of the sold tonnage observed between 1999 and 2009, is mainly due to the use of new antimicrobials replacing antimicrobials belonging to older classes like Tetracyclines and Sulfonamides. Fluoroquinolones and Cephalosporins are considered as critically important antimicrobials for human health and the increase of their use in veterinary medicine is worrying. According to European recommendations (European Medicine Agency reflection paper ion the use of Cephalosporins and Fluoroquinolones) these antimicrobials should be second intent antimicrobials and reserved to curative treatment. The data collected allow to follow the evolution of the antimicrobial sales and to have an estimation of their use in veterinary medicine. Information is one indicator to evaluate the impact of actions implemented in term of responsible use of antimicrobials. 3

7 Contents Introduction Material and methods Results for Results presented by antimicrobial class and route of administration Results expressed in weight of active ingredient Results expressed as proportion of antimicrobial treatment Results presented by animal species Results presented by category of animals Results presented by target species Evolution of antimicrobial sales between 1999 and Overall evolution of antimicrobial sales Results expressed in weight of active ingredient Results expressed in weight of animal treated Evolution of antimicrobial sales per antimicrobial class Results expressed in weight of active ingredient Results expressed in weight of active ingredient related to animal population Results expressed in weight of animal treated Results expressed as Animal Level of Exposure to Antimicrobials (ALEA) Comparison of different outputs to describe the evolution of antimicrobial sales Evolution of antimicrobial sales per animal species Discussion Conclusion

8 Annex...33 Annex 1: Parameters for calculation of animal body weight potentially treated by antimicrobials between 1999 and à 2009 Annex 2: Amount of active ingredient per substance to treat orally one ton of bodyweight) Annex 3: Comparison between the bodyweight treated by ingredient or by medicinal product Annex 4: Repartition of antimicrobial sales by antimicrobial class for each species Annex 5: Evolution of bodyweight treated for bovine, pig, poultry, dogs and cats 5

9 Introduction Antimicrobial resistance is a public health issue concerning both human and veterinary medicine. Sales monitoring is one of the basic source of information to be used for risk assessment and risk management. The National Agency for Veterinary Medicinal products (French agency for food, environment and occupational health safety previously called French Food Safety Agency) has initiated a sales survey for veterinary antimicrobials products in This survey is performed according to the OIE guideline on monitoring of antimicrobials (in Animal Terrestrial Code 2009 Chapter 6.8). This survey is based on marketing authorization holders declarations following an agreement with the SIMV (Syndicat de l industrie du médicament vétérinaire et réactifs). Data should be compared to other sources of information such as annual turnover of applicant supplier medicinal veterinary products and farm surveys on antimicrobial consumptions. The present report describes the veterinary antimicrobial sales for 2009 and includes a study on the previous year s results. 1. Material and Methods 1-1. Basic sources of information - Information provided by the Marketing Authorization Holder The monitoring is based on a questionnaire sent annually to each Marketing Authorisation Holder who has registered in France a veterinary medicinal product containing antimicrobials. Marketing Authorisation Holders are asked to declare the number of units sold for each commercial presentation of each veterinary medicinal product. In 2009, the applicants were required to provide also information about the repartition between species. These figures should be supplied for the period from 1 st January to 31 st December of the previous year and cover all Medicinal products sold. - Data about the French animal population In order to take into account fluctuations in animal population in the interpretation of data, information published by Agreste 1 are used for food producing animals. For pets, data are provided by FACCO 2 (Employers' federation of Food Manufacturers for Dogs, Cats, Birds and other familiar animals), data are available every two years

10 For fishes, data provided by Aquamedia 3 are used. - Information about the posology and the treatment duration The dose and treatment duration retained for each active ingredient for the oral route administrated to food animal producing are detailed in annex 2. For each intramammary and injectable product, the dosage and duration of administration from the French SPC have been retained Data validation In order to check for any declaration errors, sales volumes declarations are compared to annual turnover declarations provided independently by marketing authorisation holders. Any difference in declarations is investigated Calculation and interpretation The sales data for each presentation are cross-referenced with data available in the French Agency of Veterinary Medicinal Products database (qualitative and quantitative composition, pharmaceutical form, target species ). Calculations are performed to express the sales in weight of active ingredient. For some active substances expressed in IU, a conversion factor (OMS standard value) has been used: 3200 IU for 1 mg of Spiramycin 8403 IU for 1 mg of Polymyxin B IU for 1 mg of Colistin sulphate IU for 1 mg of Colistine méthane sulphonate 74 IU for 1 mg of Bacitracin 820 IU for 1 mg of Dihydrostreptomycin 920 IU for 1 mg of Erythromycin 620 IU for 1 mg of Gentamicin. These conversion factors have been updated for the survey 2009 taking into account recommendations of the European Medicines agency (EMA) in the framework of the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project

11 Repartition between species It is difficult to give figures for each animal species as a same veterinary medicinal product can be indicated for use in several species, therefore an estimation of sales per species has to be performed. In 2009, the applicants were required to provide information about the repartition between species for each commercial presentation. We have received information about this repartition for 60.7 % of the presentations of veterinary medicine products targeted to more than one species. Globally, including the products targeted to only one species, information for 74 % of the presentations of marketed products are available. Information is available for 88.2 % of the total sold tonnage. For the veterinary medicine products without information on the species repartition, an extrapolation of the repartition was done from antimicrobials of the same class and same route of administration. This methodology has been applied retrospectively to the sales between 1999 and Expression of results In this report, different outputs are provided: - Results expressed in weight of the active ingredient (Wacti) This way of expressing results is the most direct and usual way. However, if it enables to see evolution during time, it does not represent accurately the use of antimicrobials as differences in dosages and durations of administration are not taken into account. It does not enable comparison between classes of antimicrobials and does not take also into account changes in animal populations. - Results in weight of the active ingredient related to the animal population weight (Wacti/WAP) This indicator improves the expression of antimicrobial sales in taking into account changes in animal populations. However, it does not take into account the dose and treatment duration. This constitutes a better estimate of the use and enables to give results expressed in quantity of active by Kg of animal weight. - Results expressed in Weight of Animal Treated (WAT) The weight of animal treated with the antimicrobial class is obtained by dividing the sales volume expressed in weight of active ingredient by (dose multiplied by Treatment duration). The dose and treatment duration retained for the different substances administered orally to food producing animals are presented in annex 2. For each intramammary and injectable product, the dosage and duration of administration in the French SPC have been retained. In this report, the weight of animal treated has been calculated by active ingredient, to evaluate the exposure per class. As several veterinary medicine products are asociated, the weight of animal treated assessed by active ingredient is higher than the weight of animal 8

12 treated estimated by product (see annex 3). The weight of animal treated is linked to the recommended doses and treatment durations which may be different from those prescribed. WAT takes into account the dose and duration of administration but doesn t take into account the weight of animal population. This constitutes a better estimate of the use of the different antimicrobial classes than the weight of the active ingredient and allows to estimate the relative part of the treatments performed for each antimicrobial class. - Results presented as exposure index (ALEA) (Animal Level of Exposure to Antimicrobials) The antimicrobial exposure index is obtained by dividing WAT by the Potential Animal Weight treated (WAP). It takes into account the animal population as well as dose and treatment duration. As figures concerning the animal population are usually expressed in number of animals, it is necessary to estimate a mean weight for each animal species in order to obtain the potential weight to be treated (WAP= Weight of Animal Population). Calculated WAP are provided in annex 1. The estimation of animal level of exposure to antimicrobials could be improved in taking into account the weight of animal at treatment instead of the total weight of animals in the country. This index may also enable comparisons between countries. The ALEA index is an estimate that is directly correlated to the number of animal treated in the population. 9

13 Data Wacti Weight Active declared Dose Number of mg active / Kg body weight Duration Number of days of treatment WAP Weight of animal population potentially treated(total) Outputs Wacti Weight Active Wacti/WAP Weight Active declared/ Weight of animal population WAT Weight of animal treated : Wacti/(Dose*Duration) ALEA Animal Level of Exposure to Antimicrobials Takes into account Enables comparison between Outputs Calculation Units Sales Dose Duration Animal Pop AM Classes Species Countries Animal and Human Representative of exposure Wacti Weight active Tons mg/kg Animal Wacti/WAP (1000*Wacti)/WAP weight Wacti/(Dose*duration) Tons WAT ALEA WAT/ Weight Animal population Ratio

14 1-4. Main changes for the 2009 report in comparison to previous reports The weights of active ingredients for some classes for the previous years may differ from those provided in the previous reports, as new conversion (IU/mg) have been used for some antimicrobials. The repartition between species has been modified and is based on data provided by marketing authorisation holders. The weight of animal treated for injectable products has been assessed by active ingredient and not by medicinal product. 11

15 2. Results for Results presented by antimicrobial class and route of administration Results expressed in weight of active ingredient Table 1: Distribution of each antimicrobials family per route of administration (in tons of active ingredient) Sales 2009 Oral Parenteral Intramammary (in tons) External Total Percentage Aminoglycosides % Cephalosporins 1 & 2G % Cephalosporins 3 & 4G % Other % Fluoroquinolones % Furans % Macrolides % Penicillins % Phenicols % Polymyxins % Quinolones % Sulfonamides % Tetracyclines % Trimethoprim % Total (in tons) % Percentage 87.08% 11.73% 0.80% 0.40% % In 2009, the total sales volume accounts for tons of antimicrobials. As for previous surveys, 4 antimicrobial classes (Tetracyclines, Sulfonamides, Penicillins and Macrolides) account for more than 80 % of the total antimicrobial sales. The Tetracyclines class represents alone about half of the sales. Fluoroquinolones and Cephalosporins volumes are relatively low. 12

16 The following table gives the relative distribution of each antimicrobial class per route of administration. Table 2: Relative distribution of each antimicrobials class expressed in percentage for each route of administration (%) Sales 2009 Oral Parenteral Intramammary External Aminoglycosides 3.14% 31.75% 26.90% 4.96% Cephalosporins 1 & 2G 0.54% 0.10% 16.97% 1.18% Cephalosporins 3 & 4G 0.00% 1.27% 2.73% 0.00% Other 1.84% 0.57% 3.96% 0.00% Fluoroquinolones 0.28% 1.82% 0.00% 0.24% Furans 0.00% 0.00% 0.00% 0.00% Macrolides 7.54% 8.22% 1.25% 0.47% Penicillins 5.52% 41.03% 33.21% 8.98% Phenicols 0.00% 3.80% 0.00% 5.44% Polymyxins 6.93% 0.41% 0.14% 0.24% Quinolones 0.81% 0.02% 0.00% 0.00% Sulfonamides 19.11% 3.91% 0.00% 28.84% Tetracyclines 51.31% 6.73% 14.83% 48.94% Trimethoprim 2.98% 0.37% 0.00% 0.00% Percentage % % % % 13

17 2.1.2 Results expressed in weight of active ingredient (Wacti) and in weight of animal treated (WAT) The weight of animal treated by the antimicrobial classes has been obtained by dividing the weight of active ingredient of each active by the amount of antimicrobial required to treat one kg of animal (recommended doses and treatment durations which may be different from those prescribed). The weight of animal treated has been summed up for each antimicrobial class and divided by the sum of WAT of all classes of antimicrobials for the oral, the parenteral and the intramammary routes. Results obtained in weight of active ingredients and in weight of animal treated expressed in percentage are compared in the following table. Table 3. Comparison by route of administration of the results obtained using the Weight of active ingredients (Wacti) and the relative Weight of Animals Treated (WAT). Oral Parenteral Intra-mammary Sales 2009 Wacti WAT Wacti WAT Wacti WAT Aminoglycosides 3.14% 2.64% 31.75% 17.20% 26.90% 19.69% Cephalosporins 1 & 2 G 0.54% 0.11% 0.10% 0.04% 16.97% 14.22% Cephalosporins 3 & 4 G 0.00% 0.00% 1.27% 7.66% 2.73% 6.49% Others 1.84% 2.63% 0.57% 0.78% 3.96% 22.28% Fluoroquinolones 0.28% 1.34% 1.82% 7.59% 0.00% 0.00% Furans 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% Macrolides 7.54% 3.64% 8.22% 13.26% 1.25% 0.73% Penicillins 5.52% 10.98% 41.03% 32.97% 33.21% 19.12% Phenicols 0.00% 0.01% 3.80% 3.61% 0.00% 1.29% Polymyxins 6.93% 35.05% 0.41% 2.45% 0.14% 0.00% Quinolones 0.81% 1.23% 0.02% 0.01% 0.00% 0.00% Sulfnamides 19.11% 9.66% 3.91% 1.59% 0.00% 0.00% Tetracyclines 51.31% 27.11% 6.73% 11.64% 14.83% 16.18% Trimethoprim 2.98% 5.59% 0.37% 1.20% 0.00% 0.00% Percentage % % % % % % Results expresses in weight of animals treated give a better picture of the use of antimicrobials. For the oral route, sales expressed in the weight of animal treated show that treatments with Polymyxins are the most frequent treatments used followed by Tetracyclines. For the parenteral route, Penicillins are the most frequent treatments used followed by Aminoglycosides, Macrolides, and Tetracyclines. The weight of animal treated with Fluoroquinolones and 3 rd & 4 th generation Cephalosporins represent respectively 7.59% and 7.66 % of the total weight of animal treated with injectable products. 14

18 2.2. Results presented by animal species Results presented by category of animals A first way of approaching the repartition between species is to present data using categories of animals according to veterinary medicinal products indications (Food producing animals, Companion animals, Food producing and companion animals). This enables to have a first estimate of the use of antimicrobials in these different categories. Table 4. Repartition for each antimicrobials class by animal category (in tons of active ingredient) Sales 2009 Food animals Food animals and companion animals Companion animals Total (in tons) Aminoglycosides Cephalosporins 1 & 2G Cephalosporins 3 & 4G Others Fluoroquinolones Furans Macrolides Penicillins Phenicols Polymyxins Quinolones Sulfonamides Tetracyclines Trimethoprim Total (in tons) Antimicrobials intended for food producing animals only account for more than 92 % of the total antimicrobials sales. Furans are only intended for use in companion animals. 15

19 2.2.2 Results per species Sales by species have been expressed in percentage of total weight of active ingredient and in percentage of total weight of animal treated, detailed tables are available in annex 4. Cattle Table 5. Antimicrobials sales repartition by species according to different outputs Cat - Dog Horse Fish Rabbit Sheep- Goat Swine Poultry Others Total Wacti % % 1.83 % 0.51 % 0.24 % 7.82 % 7.18 % % % 0.01 % 100 % WAT % % 3.24 % 1.24 % 0.09 % 3.37 % 4.73 % % % 0.01 % 100 % - Wacti Weight of active ingredient This output allows to estimate that nearly 44 % of the sold tonnage of antimicrobials is intended for pigs, more than 22 % is intended for poultry. When expressed in active ingredients, results are not representative of the exposure to antimicrobials of the animal species. - WAT Weight of animal treated: Wacti/(Dosage*Duration) Nearly 30 % of the weight of animal treated relates to cattle, almost 33 % to swine and 25 % to poultry. Expressing results in weight of animals treated takes into account posology and duration of treatments but does not take into account the population treated. When the mass of the population potentially treated is taken into account this gives a better picture of the use of antimicrobials in the different species (e.g. table 6). Cattle Table 6. Antimicrobials sales by species expressed in mg/kg and in ALEA Cat - Dog Horse Fish Rabbit Sheep- Goat Swine Poultry Others Total Wacti/Wap mg/kg ALEA In 2009, sales correspond to an equivalent of mg/kg of animal weight produced. 16

20 - ALEA Index of animal level of exposure to antimicrobials The ALEA factor represents the best the exposure to antimicrobials as it takes into account the dose administered, the duration of treatment as well as the animal population potentially treated. If the ALEA is equal to 1, it means that the weight of animal treated is exactly the same than the weight of population animal. An ALEA of 33 % for cattle means that in 2009, the sales intended for cattle have been used to treat 33 % of the bodyweight of cattle produced in France This shows that cats and dogs, rabbits, pigs and poultry are the most exposed species to antimicrobial treatments. These figures should be taken with caution as the use in young and older animals can be different. So for cattle, the antimicrobials administrated by the oral route are intended only to veals, our estimation shows that the ALEA for veals is close to the ALEAs for swine and poultry. The assessment of animal level of exposure to antimicrobials may be improved in taking into account the weight of animal during the treatment instead of the total weight of animals in the country. 17

21 3. Evolution of antimicrobial sales between 1999 and Overall evolution of antimicrobial sales Results expressed in weight of active ingredient Table 7. Evolution of weight of active ingredient according to the route of administration (Wacti) Oral including premixes Parenteral Intra-mammary External Total (in tons) During the 11 years survey, the total antimicrobial sales range between and tons sales represent the lowest sales volume recorded during the 11 years period. In 2009, the total antimicrobials sales have decreased from % compared to 2008 and from % compared to 1999, these decrease is principally due to a decrease of oral administered antimicrobials Results expressed in weight of animal treated 4 The weight of animal treated can be calculated by active ingredients or by medicinal product. The calculation by active ingredient is an estimate of the exposure to each active ingredient and is representative of the exposure to antimicrobial or to the antimicrobial family considered. The calculation by medicinal product is an estimate of the number of treatments administered (a medicinal product may contain one or several antibiotics) and is representative of the number of prescriptions of medicinal products containing antimicrobials. The expression by medicinal product or by active ingredient has a low impact regarding the global evolution as shown when comparing for the parenteral route, weight of animal treated expressed by active ingredient or by medicinal product (annex 3). In the remainder of this report, results expressed in weight of animal treated (WAT) have been calculated for each active ingredient and are representative of the evolution of the exposure to antibiotics. 4 Excluding external route 18

22 Table 8. Evolution of WAT according to the route of administration WAT In tons of WAT Oral including premixes Parenteral Total Oral + Parentéral For intra-mammary products, results are expressed in number of animals treated by product. Table 9. Evolution of the number of animals treated by intra-mammary route In number of animals treated Intra-mammary The weight of animal treated by parenteral route decreases from 14.6 % in 2009 compared to The weight of animal treated by oral route increases from 12.8 % in 2009 compared to However, a decrease is noticed for the 2 last years (a decrease of 14.4 % in 2009 compared to 2007). For the premixes, the decrease is of 32.2 % compared to The number of animals treated by intra-mammary route decreases of 15.4 % compared to 2008 and of 28.7 % compared to

23 3.2. Evolution of antimicrobial sales per antimicrobial class Results expressed in weight of the active ingredient Table 10. Evolution of sales by antimicrobial class from 1999 to 2009 (Wacti in tons) Aminoglycosides Cephalosporins 1 & 2G Cephalosporins 3 & 4G Others Fluoroquinolones Furans Macrolides Penicillins Phenicols Polymyxins Quinolones Sulfonamides Tetracyclines Trimethoprim Total (in tons) In 2009, the weight sold of antimicrobials have decreased of 13.0 % (159 tons) compared to 2008 and of 19.3 % (255 tons) compared to On the 11 years period, the 2 antimicrobial classes showing the more important decreases are Tetracyclines (decrease of 22.2 % corresponding to 139 tons) and Sulfonamides (decrease of 32.0 % corresponding to 86 tons) Compared to 1999, Fluoroquinolone sales have increased (48.94 % corresponding to 1.61 tons) while Quinolones sales have decreased (63.3 % corresponding to tons). Compared to 2008, the sales of Fluoroquinolones have stabilized in 2009 (+0.09 %) Compared to 1999, 3 rd and 4 th generation Cephalosporins sales have increased (105.6 % corresponding to 0.94 ton) as well as 1 st and 2 nd generation Cephalosporins sales (28.4 % corresponding to 1.47 tons). Compared to 2008, the sales of 3 rd and 4 th generation Cephalosporins have decreased ( corresponding to 0.29 ton). 20

24 3.2.2 Results expressed in weight of active ingredient related to animal population As figures concerning the animal population are usually expressed in number of animals, it is necessary to estimate a mean weight for each animal species in order to obtain the potential weight to be treated (WAP= Weight of Animal Population). Calculated WAP are provided in annex 1. Table 11. Evolution of weight of animal population for the main species (in tons) Cattle Swine Poultry Fish Cat-dog Sheep-goat Rabbit Others Total Table 12. Evolution of sales by antimicrobial class from 1999 to 2009 related to weight of animal population (Wacti/WAP) mg/kg Aminoglycosides Cephalosporins 1 & 2G Cephalosporins 3 & 4G Other Fluoroquinolones Furans Macrolides Penicillins Phenicols Polymyxins Quinolones Sulfonamides Tetracyclines Trimethoprim Total (in mg/kg)

25 In 2009, sales correspond to an equivalent of mg/kg of animal weight produced. Results expressed in weight of active ingredient taking into account the animal population show nearly the same trends than results expressed in weight of active ingredient. The sales of 1 st and 2 nd generation Cephalosporins increase of 40.5 %, the sales of 3 rd and 4 th generation Cephalosporins increase of % and the sales of Fluoroquinolones increase of 62.6 %. For all the antimicrobial classes; except Penicillins, Fluoroquinolones and Polymyxins, the sales expressed in weight of active ingredient related to the animal population have decreased between 2008 and

26 3.2.3 Results expressed in Weight of animal treated (WAT) Table 13. Evolution of sales by antimicrobial class from 1999 to 2009 expressed in Weight of animal treated (WAT) in tons (parenteral and oral treatments only) Aminoglycosides Cephalosporins 1 & 2G Cephalosporins 3 & 4G Other Fluoroquinolones Furans Macrolides Penicillins Phenicols Polymyxins Quinolones Sulfonamides Tetracyclines Trimethoprim In tons of WAT When comparing 2009 and 1999 results, the weight of animal treated (WAT) increases of 3.1 %. Compared to 1999, the weight of animal treated with Fluoroquinolones has increased of 77.3 %, and the weight of animal treated with first generation Quinolones has decreased of 31.9 %. Compared to 1999, the weight of animal treated with 3 rd & 4 th generation Cephalosporins has increased of % and of 31.7% for 1 st and 2 nd generation Cephalosporins. Results expressed in WAT show also a decrease for all classes of antimicrobials in comparison to 2008, except for Polymyxins (increase of 1.7 %). In 2009 and compared to 2008, the weight of animal treated with Fluoroquinolones and with 3 rd & 4 th generation Cephalosporins both have decreased (minus 0.47 % for Fluoroquinolones, and minus 15.9 % for 3 rd & 4 th generation Cephalosporins). 23

27 3.2.4 Results expressed as Animal Level of Exposure to Antimicrobials (ALEA) Table 14. Evolution of sales by antimicrobial class from 1999 to 2009 expressed in ALEA (oral and parenteral routes only) Aminoglycosides Cephalosporins 1 & 2G Cephalosporins 3 & 4G Other Fluoroquinolones Furans Macrolides Penicillins Phenicols Polymyxins Quinolones Sulfonamides Tetracyclines Trimethoprim ALEA When comparing 2009 and 1999 results, the ALEA index, irrespective of classes and species, increases of 12.6 %. Compared to 2008, the ALEA index decreases of 3.9 %. The exposure to all generation Cephalosporins, Fluoroquinolones, Macrolides, Phenicols, Polymyxins and Tetracyclines has increased; the exposure to Aminoglycosides, Quinolones, Sulfonamides and Trimethorpim has decreased compared to Compared to 1999, the level of exposure to Fluoroquinolones has increased of 93.6 %, in the same time the exposure of Quinolones has decreased to 53.8 %. Compared to 2008, the level of exposure to Fluoroquinolones has decreased of 0.85 %. Compared to 1999, the level of exposure to 3 rd & 4 th generation Cephalosporins has increased of % and the level of exposure to 1 st and 2 nd generation Cephalosporins, has increased of 43.8 %. Compared to 2008, the level of exposure to 3 rd & 4 th generation Cephalosporins has decreased of 14.8 %. 24

28 3.2.5 Comparison of different outputs to describe the evolution of antimicrobial sales Table 15. Comparison between 2009 and 1999 sales with different indicators Wacti Wacti/WAP WAT ALEA Aminoglycosides % -4.35% % % Cephalosporins 1 & 2G 28.62% 40.46% 31.72% 43.85% Cephalosporins 3 & 4G % % % % Others 3.45% 12.97% 27.58% 39.32% Fluoroquinolones 48.91% 62.62% 77.33% 93.65% Furans % % % % Macrolides 4.09% 13.67% 13.63% 24.09% Penicillins -6.42% 2.19% -6.71% 1.87% Phenicols 5.91% 15.66% 5.72% 15.45% Polymyxins 2.99% 12.47% 31.92% 44.06% Quinolones % % % % Sulfonamides % % % % Tetracyclines % % 0.24% 9.46% Trimethoprim % % % % Evolution in 2009 related to % % 3.11% 12.60% Table 15bis. Comparison between 2009 and 2008 sales with different indicators Wacti Wacti/WAP WAT ALEA Aminoglycosides % % % % Cephalosporins 1 & 2G -3.04% -1.75% -4.43% -3.16% Cephalosporins 3 & 4G % % % % Others -3.01% -1.72% -3.09% -1.81% Fluoroquinolones 0.03% 1.36% -0.47% 0.85% Furans % % % % Macrolides % % -6.17% -4.93% Penicillins 0.35% 1.69% -0.64% 0.68% Phenicols -5.29% -4.03% -0.05% 1.28% Polymyxins 1.07% 2.41% 1.70% 3.05% Quinolones -5.96% -4.71% -2.84% -1.55% Sulfonamides -6.02% -4.77% % -9.83% Tetracyclines % % -7.13% -5.90% Trimethoprim -4.61% -3.34% -3.43% -2.15% Evolution in 2009 related to % % -5.1% -3.9% The comparison of sales, between 1999 and 2009 show different evolutions according to the output chosen. When comparing 2009 with 1999 results, the sales volume decreases of %. When taking into account the weight of the animal population potentially treated, the decrease is only of %. When expressing results in WAT, an increase of 3.11 % is seen. The ALEA index representing the animal exposure shows an increase of 12.6 %. 25

29 This latter output shows that the exposure to 3 rd & 4 th generation Cephalosporins has been multiplied by 3.5 between 1999 and 2009, and the exposure of animals to Fluoroquinolones has been multiplied by 2. When comparing 2009 results with 2008 results, the sales volume decreases of %. When taking into account the weight of animal population potentially treated, the decrease is only of %. When expressing results in WAT representing the number of treatments, a decrease of 5.1 % is seen. The ALEA index representing the animal exposure shows a decrease of 3.9 % Evolution of Antimicrobial sales per animal species for the oral and parenteral routes Results expressed in Weight of animal treated for the main target species Details figures regarding the evolution of sales by antimicrobial classes in weight of animal treated for cattle, cats and dogs, swine and poultry productions are provided in annex

30 Table 16. Evolution of the use of antimicrobial classes in cattle (except external and intramammary routes) Aminoglycosides 16.71% 16.96% 16.68% 15.54% 15.39% 15.81% 14.84% 14.74% 18.19% 18.24% 13.81% Cephalosporins 1 & 2G Cephalosporins 3 & 4G 1.73% 2.62% 2.90% 3.25% 3.98% 4.31% 4.83% 5.27% 5.52% 6.35% 5.84% Other 1.57% 1.45% 1.21% 1.21% 1.30% 1.30% 1.20% 1.11% 1.08% 1.07% 1.03% Fluoroquinolones 2.38% 2.33% 3.42% 4.27% 5.19% 4.75% 4.98% 5.54% 5.06% 5.32% 5.67% Furans Macrolides 10.96% 11.00% 11.23% 12.08% 12.87% 12.47% 13.13% 12.52% 10.35% 12.39% 13.47% Penicillins 31.57% 30.94% 30.61% 27.50% 25.12% 25.06% 24.26% 23.99% 22.91% 22.02% 23.36% Phenicols 3.08% 3.20% 3.08% 3.82% 3.11% 3.61% 3.30% 4.02% 3.69% 3.14% 3.08% Polymyxins 8.46% 8.69% 9.08% 9.55% 9.81% 9.52% 9.76% 9.99% 10.21% 10.42% 11.65% Quinolones 1.76% 1.75% 1.64% 1.49% 1.43% 1.25% 1.44% 1.43% 1.06% 0.78% 0.92% Sulfonamides 6.21% 6.12% 5.64% 5.26% 4.93% 5.23% 5.23% 5.14% 6.73% 6.84% 5.54% Tetracyclines 14.02% 13.48% 12.81% 14.10% 15.01% 14.73% 15.21% 14.61% 13.77% 11.82% 13.91% Trimethoprim 1.56% 1.46% 1.70% 1.93% 1.86% 1.96% 1.82% 1.65% 1.44% 1.60% 1.70% Percentage % % % % % % % % % % % Bovine: distribution of antimicrobial classes in WAT % 35,00% 30,00% 25,00% 20,00% 15,00% 10,00% 5,00% 0,00% According to the estimations, during the last 11 years, the parts of Aminoglycosides, Penicillins, and Quinolones in the bodyweight of bovines treated with antimicrobials have decreased, whereas the parts of 3 rd and 4 th generation Cephalosporins, Fluoroquinolones, Macrolides and Polymixins increased. 27

31 Table 17. Evolution of the use of antimicrobial classes in dogs and cats (except external route) Aminoglycosides 8.25% 8.76% Cephalosporins 1 & 2G 3.25% 3.40% Cephalosporins 3 & 4G 0.00% 0.00% Other 12.59% 10.80% Fluoroquinolones 17.12% 16.66% Furans 0.55% 0.54% Macrolides 2.77% 3.19% Penicillins 37.98% 38.51% Phenicols 0.22% 0.21% Polymyxins 0.86% 0.85% Quinolones 0.12% 0.40% Sulfonamides 10.61% 11.00% Tetracyclines 3.78% 3.83% Trimethoprim 1.92% 1.86% Percentage % % % 8.01% 7.16% 7.56% 6.41% 5.60% 5.18% 5.01% 4.40% 3.86% 3.75% 3.56% 3.67% 3.54% 3.15% 2.92% 2.82% 2.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.20% 1.11% 1.32% 1.46% 9.93% 12.70% 11.68% 12.38% 18.84% 23.99% 25.35% 27.18% 27.65% 20.51% 21.91% 18.75% 20.37% 16.51% 13.51% 14.33% 13.81% 15.20% 0.47% 0.40% 0.36% 0.32% 0.26% 0.21% 0.20% 0.18% 0.14% 3.21% 3.64% 2.62% 2.76% 2.29% 2.69% 1.75% 1.64% 1.53% 37.47% 34.38% 43.41% 40.10% 41.42% 41.70% 40.47% 39.81% 39.90% 0.22% 0.21% 0.19% 0.18% 0.17% 0.15% 0.13% 0.11% 0.09% 0.81% 0.73% 0.67% 0.58% 0.51% 0.44% 0.34% 0.35% 0.30% 0.33% 0.47% 0.32% 0.24% 0.23% 0.03% 0.10% 0.02% 0.05% 9.42% 8.89% 7.23% 7.71% 5.87% 5.12% 4.91% 4.81% 3.92% 3.67% 3.57% 3.12% 3.20% 3.28% 2.64% 2.72% 2.50% 2.35% 1.64% 1.33% 0.94% 0.93% 0.67% 0.56% 0.50% 0.45% 0.38% % % % % % % % % % Dogs and cats : Distribution of antimicrobial classes expressed in WAT % 45,00% 40,00% 35,00% 30,00% 25,00% 20,00% 15,00% 10,00% 5,00% 0,00% According to the estimations, during the last 11 years, the parts of 3 rd and 4 th generation Cephalosporins, of others antimicrobials and of Penicillins in the bodyweight of dogs and cats treated with antimicrobials have increased. 28

32 Table 18. Evolution of the use of antimicrobial classes in pigs (except external route) Aminoglycosides 5.19% 5.47% Cephalosporins 1 & 2G - - Cephalosporins 3 & 4G 0.32% 0.38% Other 1.86% 2.34% Fluoroquinolones 1.06% 1.13% Furans - - Macrolides 3.96% 4.16% Penicillins 12.81% 13.11% Phenicols 0.00% 0.00% Polymyxins 29.84% 29.52% Quinolones 2.64% 1.66% Sulfonamides 7.69% 7.47% Tetracyclines 28.66% 29.05% Trimethoprim 5.99% 5.72% Percentage % % % 5.56% 5.10% 4.98% 4.88% 4.64% 4.19% 4.06% 4.22% % 0.42% 0.48% 0.52% 0.68% 1.28% 1.28% 1.39% 1.35% 2.65% 2.98% 2.64% 2.44% 2.20% 1.91% 1.76% 1.82% 1.69% 1.19% 1.36% 1.49% 1.48% 1.69% 1.76% 1.39% 1.82% 1.94% % 5.57% 5.19% 5.17% 5.11% 5.41% 4.81% 4.81% 4.89% 12.65% 12.97% 11.72% 11.54% 11.48% 12.01% 11.43% 10.94% 12.45% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.47% 29.70% 29.41% 31.75% 31.27% 31.45% 31.74% 33.32% 33.84% 33.73% 1.12% 1.00% 0.77% 0.89% 0.90% 0.84% 0.74% 0.72% 0.61% 6.67% 6.78% 6.00% 6.53% 6.30% 6.66% 6.79% 6.98% 7.02% 29.83% 28.31% 29.68% 29.59% 30.04% 28.35% 28.97% 28.07% 26.09% 5.40% 5.64% 5.18% 5.59% 5.29% 5.40% 5.32% 5.52% 5.54% % % % % % % % % % Porcine: Distribution ofantimicrobial classes expressed in WAT % 35,00% 30,00% 25,00% 20,00% 15,00% 10,00% 5,00% 0,00% According to the estimations, during the last 11 years, the parts of Aminoglycosides, of Sulfonamides, Trimethoprim, Penicillins, Quinolones and Tetracyclines in the bodyweight of pigs treated with antimicrobials have decreased, whereas the parts of 3 rd and 4 th generation Cephalosporins, Fluoroquinolones, Macrolides, Phenicols and Polymixins have increased. 29

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France Volumes and estimated exposure of animals to antimicrobials

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France Volumes and estimated exposure of animals to antimicrobials Sales survey of Veterinary Medicinal Products containing Antimicrobials in France - 2013 Volumes and estimated exposure of animals to antimicrobials October 2014 Scientific Edition Sales survey of Veterinary

More information

Sales survey of veterinary medicinal products containing antimicrobials in France in Annual report

Sales survey of veterinary medicinal products containing antimicrobials in France in Annual report Sales survey of veterinary medicinal products containing antimicrobials in France in 2016 Annual report October 2017 Scientific edition Sales survey of veterinary medicinal products containing antimicrobials

More information

Antimicrobial use and Antimicrobial resistance: chapter 6.7 and 6.8 of the OIE Terrestrial Animal Health

Antimicrobial use and Antimicrobial resistance: chapter 6.7 and 6.8 of the OIE Terrestrial Animal Health Workshop for OIE national Focal Points for Veterinary Products (2 nd cycle) Vienna (Austria), 20-22 November 2012 Antimicrobial use and Antimicrobial resistance: chapter 6.7 and 6.8 of the OIE Terrestrial

More information

OIE initiative establishing a global database on consumption of antimicrobials for animals: state of play

OIE initiative establishing a global database on consumption of antimicrobials for animals: state of play OIE initiative establishing a global database on consumption of antimicrobials for animals: state of play European Surveillance of Veterinary Antimicrobial Consumption stakeholders meeting, London, UK,

More information

Guidance for completing the OIE template for the collection of data on antimicrobial agents intended for use in animals

Guidance for completing the OIE template for the collection of data on antimicrobial agents intended for use in animals Guidance for completing the OIE template for the collection of data on antimicrobial agents intended for use in animals Contents Introduction... 1 Required information and choices for reporting... 2 Baseline

More information

ESVAC (European Surveillance of Veterinary Antimicrobial Consumption)

ESVAC (European Surveillance of Veterinary Antimicrobial Consumption) ESVAC (European Surveillance of Veterinary Antimicrobial Consumption) Present and future activities 60th Meeting of the EFSA advisory forum Presented J. Torren, Scientific Administrator, Animal and Public

More information

Working group session

Working group session Working group session OIE Data Collection Improvement on the Possible Reporting Options Bangkok, March 2018 Reporting Options The sections of the OIE Template named Reporting Options 1, 2 and 3, collect

More information

Result of the OIE data collection

Result of the OIE data collection Delfy Góchez Chargée de mission Result of the OIE data collection Lessons learned and expectations Beirut, November 8th 2017 Reporting Options The sections of the OIE Template named Reporting Options 1,

More information

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Web Based Sales Data and Animal Population Data Collection Protocol (version 2)

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Web Based Sales Data and Animal Population Data Collection Protocol (version 2) 20 June 2016 EMA/210691/2015-Rev.1 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Web Based Sales Data and Animal Population Data Collection Protocol

More information

Antimicrobial Resistance Actions undertaken by the Anses (alternatives to AM)

Antimicrobial Resistance Actions undertaken by the Anses (alternatives to AM) Antimicrobial Resistance Actions undertaken by the Anses (alternatives to AM) Charlotte Grastilleur, risk assessment departement, deputy head (food and health) Mapping of structures involved at Anses Coordination

More information

BTSF. Better Training for Safer Food Initiative. Antimicrobial Resistance One Health approach MEASURE UNITS

BTSF. Better Training for Safer Food Initiative. Antimicrobial Resistance One Health approach MEASURE UNITS Better Training for Safer Food Initiative Antimicrobial Resistance One Health approach MEASURE UNITS BTSF This presentation is delivered under contract with the Consumers, Health, Agriculture and Food

More information

Antimicrobial use in animals: OIE collection of data on antimicrobial agents used in animals (2015)

Antimicrobial use in animals: OIE collection of data on antimicrobial agents used in animals (2015) Antimicrobial use in animals: OIE collection of data on antimicrobial agents used in animals (2015) OIE antimicrobialuse team with the support of Dr Gérard Moulin ESVAC Stakeholders annual meeting London,

More information

Collection of quantitative data on the use of antimicrobial agents including the establishment of an OIE database

Collection of quantitative data on the use of antimicrobial agents including the establishment of an OIE database Collection of quantitative data on the use of antimicrobial agents including the establishment of an OIE database OIE Regional Workshop for OIE National Focal Points for Veterinary Products Maputo, Republic

More information

Activities and achievements related to the reduction in antibiotics use and resistance in veterinary medicine in Belgium in 2016

Activities and achievements related to the reduction in antibiotics use and resistance in veterinary medicine in Belgium in 2016 Activities and achievements related to the reduction in antibiotics use and resistance in veterinary medicine in Belgium in 2016 1 Activities and achievements antibiotics use and resistance among animals

More information

European Medicines Agency role and experience on antimicrobial resistance

European Medicines Agency role and experience on antimicrobial resistance European Medicines Agency role and experience on antimicrobial resistance Regional Training Workshop on Antimicrobial Resistance (AMR) Responding to the global challenge of AMR threats: toward a one health

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND

More information

Antimicrobial use in humans

Antimicrobial use in humans Antimicrobial use in humans Ann Versporten Prof. Herman Goossens OIE Global Conference on the Responsible and Prudent Use of Antimicrobial Agents for Animals - 13 March 2013 - Ann.versporten@ua.ac.be Herman.goossens@uza.be

More information

European Public MRL assessment report (EPMAR)

European Public MRL assessment report (EPMAR) 18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3

More information

prof. Jozef Bires, DVM, DSc. Chief Veterinary Officer The State Veterinary and Food Administration of the SR

prof. Jozef Bires, DVM, DSc. Chief Veterinary Officer The State Veterinary and Food Administration of the SR prof. Jozef Bires, DVM, DSc. Chief Veterinary Officer The State Veterinary and Food Administration of the SR Slovakia has a population of over five and a half million inhabitants and an area of about 49,000

More information

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) 12 April 2013 E/85298/2012 Veterinary Medicines and Product Management European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Background The European Commission has requested the European

More information

Fight against Antimicrobial Resistance Contribution of a private veterinary organization. REMESA, Faro, Portugal Christophe BRARD, 14th June 2013,

Fight against Antimicrobial Resistance Contribution of a private veterinary organization. REMESA, Faro, Portugal Christophe BRARD, 14th June 2013, Fight against Antimicrobial Resistance Contribution of a private veterinary organization REMESA, Faro, Portugal Christophe BRARD, 14th June 2013, N 2 Organisation de la profession vétérinaire Conseil Supérieur

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur... SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.

More information

Antibiotic Sales and Use Overview Prepared for Approvals and ACVM Group. ISBN No: (online)

Antibiotic Sales and Use Overview Prepared for Approvals and ACVM Group. ISBN No: (online) Antibiotic Sales and Use Overview 2004-2009 Prepared for Approvals and ACVM Group ISBN No: 978-0-478-38448-2 (online) December 2010 Disclaimer Every effort has been made to ensure the information in this

More information

ARCH-Vet. Summary 2013

ARCH-Vet. Summary 2013 Federal Department of Home Affairs FDHA FSVO ARCH-Vet Report on sales of antibiotics in veterinary medicine and antibiotic resistance monitoring of livestock in Switzerland Summary 2013 Published by Federal

More information

Summary of the latest data on antibiotic consumption in the European Union

Summary of the latest data on antibiotic consumption in the European Union Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite

More information

Session 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound

Session 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound Session 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound veterinary drugs February 13, 2018 Webinar Presentation

More information

FACT SHEETS. On the Danish restrictions of non-therapeutical use of antibiotics for growth promotion and its consequences

FACT SHEETS. On the Danish restrictions of non-therapeutical use of antibiotics for growth promotion and its consequences 12 July 2010 FACT SHEETS On the Danish restrictions of non-therapeutical use of antibiotics for growth promotion and its consequences Denmark is a major livestock producer in Europe, and the worlds largest

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

More information

Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health

Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health Regional Workshop for National Focal Points for Veterinary Products

More information

Global animal production perspectives and correlated use of antimicrobial agents

Global animal production perspectives and correlated use of antimicrobial agents Global animal production perspectives and correlated use of antimicrobial agents Barbara Freischem Executive Director, International Federation for Animal Health (IFAH) General Overview Presentation overview

More information

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE

More information

ECDC-EFSA-EMA Joint Opinion on Outcome Indicators on Surveillance of Antimicrobial Resistance and Use of Antimicrobials

ECDC-EFSA-EMA Joint Opinion on Outcome Indicators on Surveillance of Antimicrobial Resistance and Use of Antimicrobials ECDC-EFSA-EMA Joint Opinion on Outcome Indicators on Surveillance of Antimicrobial Resistance and Use of Antimicrobials P.-A. Belœil (EFSA) and D. Monnet (ECDC) One Health Network on Antimicrobial Resistance

More information

OIE Strategy on Antimicrobial Resistance and the need for new diagnostic tools

OIE Strategy on Antimicrobial Resistance and the need for new diagnostic tools Dr Elisabeth Erlacher-Vindel Head Science and New Technologies Department OIE Strategy on Antimicrobial Resistance and the need for new diagnostic tools 12 th OIE SEMINAR 18 th WAVLD, Sorrento (Italy),

More information

EMA advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials

EMA advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials EMA advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials Helen Jukes, CVMP member EMA/IFAH-Europe Info Day, 12 March 2015

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active

More information

EC Workshop on scientific advice from AMEG

EC Workshop on scientific advice from AMEG EC Workshop on scientific advice from AMEG Brussels, 26 Nov 2015 Session 2: Antibiotic Categorisation AMEG Q2 Karolina Törneke / Helen Jukes Liability disclaimer: The views or positions expressed in this

More information

Antibiotic usage in the British sheep industry. Dr Peers Davies

Antibiotic usage in the British sheep industry. Dr Peers Davies Antibiotic usage in the British sheep industry Dr Peers Davies 40% of all livestock biomass in the UK (ESVAC report 2016) Current Estimates and Data Sources No published, quantitative estimates of antimicrobial

More information

OIE Strategy on Antimicrobial Resistance and the Prudent Use of Antimicrobials in Animals Part I

OIE Strategy on Antimicrobial Resistance and the Prudent Use of Antimicrobials in Animals Part I Dr Elisabeth Erlacher-Vindel Head of the Antimicrobial Resistance and Veterinary Products Department OIE Strategy on Antimicrobial Resistance and the Prudent Use of Antimicrobials in Animals Part I 2nd

More information

Livestock Quality Assurance Education for Youth Producers 2017

Livestock Quality Assurance Education for Youth Producers 2017 Livestock Quality Assurance Education for Youth Producers 2017 As a Livestock Producer: You have an important and responsible role in food production and food safety. You are visible; you are the face

More information

CIPARS The Canadian Integrated Program for Antimicrobial Resistance Surveillance. Highlights from 2016

CIPARS The Canadian Integrated Program for Antimicrobial Resistance Surveillance. Highlights from 2016 CIPARS The Canadian Integrated Program for Antimicrobial Resistance Surveillance Highlights from 2016 Agenda and Presentation Outline Welcome and technical information Meeting objective Program overview

More information

General Directorate of Animal Health and EpizooticDiseases Control. Dr.Sabah Hassan Abdelgadir Sudan Focal Point for Veterinary products

General Directorate of Animal Health and EpizooticDiseases Control. Dr.Sabah Hassan Abdelgadir Sudan Focal Point for Veterinary products REPUBLIC OF SUDAN Ministry of Animal Resources General Directorate of Animal Health and EpizooticDiseases Control Dr.Sabah Hassan Abdelgadir Sudan Focal Point for Veterinary products Sudan experiences

More information

Activities and achievements regarding the reduction in the use of antibiotics and antimicrobial resistance in veterinary medicine in Belgium in 2017

Activities and achievements regarding the reduction in the use of antibiotics and antimicrobial resistance in veterinary medicine in Belgium in 2017 Activities and achievements regarding the reduction in the use of antibiotics and antimicrobial resistance in veterinary medicine in Belgium in 2017 1 Table of contents Context... 2 Summary... 2 Covenant

More information

CLSI vs. EUCAST. What is EUCAST? Structure of EUCAST CLSI. Where they fit? SASCM WORKSHOP 5/24/2014

CLSI vs. EUCAST. What is EUCAST? Structure of EUCAST CLSI. Where they fit? SASCM WORKSHOP 5/24/2014 vs. Olga Perovic, Principal Pathologist, Center for Opportunistic, Tropical and Hospital Infections, Associate Professor at WITS, Saturday, May 24, 2014 A not-for-profit membership organization, the Clinical

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals 1.B1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMOXYCOL Soluble Powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin trihydrate 640.0

More information

How is Ireland performing on antibiotic prescribing?

How is Ireland performing on antibiotic prescribing? European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg

More information

OIE Resolution and activities related to the Global Action Plan. Regional Seminar for OIE National Focal Points for Veterinary Products 4 th Cycle

OIE Resolution and activities related to the Global Action Plan. Regional Seminar for OIE National Focal Points for Veterinary Products 4 th Cycle Dr Elisabeth Erlacher Vindel Deputy Head of the Scientific and Technical Departement World Organisation for Animal Health (OIE) OIE Resolution and activities related to the Global Action Plan Regional

More information

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:

More information

Information note regarding the Danish and EU restrictions of non-therapeutical use of antibiotics for growth promotion

Information note regarding the Danish and EU restrictions of non-therapeutical use of antibiotics for growth promotion 12.08.2009 Information note regarding the Danish and EU restrictions of non-therapeutical use of antibiotics for growth promotion Denmark is a major animal food producer in Europe, and the worlds largest

More information

PROFESSIONAL PRACTICE STANDARD

PROFESSIONAL PRACTICE STANDARD PROFESSIONAL PRACTICE STANDARD Dispensing Drugs TBD Introduction Under the Veterinarians Act and Regulations, veterinarians licensed by the College of Veterinarians of Ontario are authorized to engage

More information

CVMP strategy on antimicrobials

CVMP strategy on antimicrobials 1 2 3 6 November 2015 EMA/CVMP/209189/2015 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 Draft Adoption by CVMP for release for consultation 6 November 2015 Start of public consultation

More information

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RABORAL V-RG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION For 1 dose: Active substance: -

More information

Antimicrobial consumption

Antimicrobial consumption Antimicrobial consumption Annual Epidemiological Report for 2017 Key facts Twenty-seven countries, comprising 25 EU Member States and two EEA countries (Iceland and Norway) reported data on antimicrobial

More information

Norwegian policies to address antimicrobial resistance

Norwegian policies to address antimicrobial resistance Norwegian policies to address antimicrobial resistance Frode Forland, Specialist Director, Division of Infectious Control and Environmental Health, Norwegian Institute of Public Health Karianne Johansen,

More information

Control and monitoring of the use of antibiotics as a strategy against antimicrobials resistance

Control and monitoring of the use of antibiotics as a strategy against antimicrobials resistance Control and monitoring of the use of antibiotics as a strategy against antimicrobials resistance Christiane Santiago Maia ANVISA - Brazilian Health Regulatory Agency s Context The burden of deaths from

More information

LABELLING AND PACKAGE LEAFLET

LABELLING AND PACKAGE LEAFLET LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.

More information

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products Quality of Veterinary Medicinal Products How to ensure the quality of Veterinary Medicinal Products Gérard Moulin Anses/ANMV OIE Collaborating Centre on Veterinary medicinal products gerard.moulin@anses.fr

More information

WHO efforts to reduce the impact on public and animal health of antibiotic use in animals. Dr Danilo Lo Fo Wong Senior Adviser AMR

WHO efforts to reduce the impact on public and animal health of antibiotic use in animals. Dr Danilo Lo Fo Wong Senior Adviser AMR WHO efforts to reduce the impact on public and animal health of antibiotic use in animals Dr Danilo Lo Fo Wong Senior Adviser AMR Antimicrobial resistance (AMR): a public and animal health issue Widespread

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BLUEVAC BTV8 suspension for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Parofor 70 mg/g powder for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs. 2. QUALITATIVE

More information

Current EU Antibiotic Maximum Residue Limits

Current EU Antibiotic Maximum Residue Limits R-Biopharm Rhône Current EU Antibiotic Maximum Residue Limits March 2011 R-Biopharm Rhône Current EU Antibiotic Limits 2 Contents Antibiotics in Food Aminoglycosides...4 Ansamycins...4 Beta-lactams...5

More information

DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme

DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme Hanne-Dorthe Emborg Department of Microbiology and Risk Assessment National Food Institute, DTU Introduction The DANMAP

More information

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including: SUMMARY OF PRODUCT CHARCTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amoxycare Suspension for Injection 15% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active Substance(s)

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 21 October 2008 EMEA/CVMP/SAGAM/428938/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER ON ANTIMICROBIAL

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR AlSap 1 suspension for injection for sheep and cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose

More information

Veterinary Feed Directive

Veterinary Feed Directive Veterinary Feed Directive Medically Important Antibiotics in Animal Agriculture Outline Questions to Be Addressed What changes are being made and why? What drugs are affected, which ones are not? What

More information

COUNTRY PRESENTATION ON RECENT ACTIVITIES CARRIED OUT BY FOCAL POINT BHUTAN

COUNTRY PRESENTATION ON RECENT ACTIVITIES CARRIED OUT BY FOCAL POINT BHUTAN COUNTRY PRESENTATION ON RECENT ACTIVITIES CARRIED OUT BY FOCAL POINT BHUTAN Regional Seminar for OIE National Focal Points for Veterinary Products (4th Cycle) Tokyo, Japan, 2-4 March 2016 1 Background/General

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dipen 100ml Suspension for Injection for cattle, sheep and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Panacur AquaSol 200 mg/ml oral suspension for use in drinking water for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: Tilmicosin 300 mg;

More information

Antimicrobial resistance (AMR): Presentation on the joint EMA/EFSA RONAFA opinion Harmonisation of SPCs of antimicrobial veterinary medicines

Antimicrobial resistance (AMR): Presentation on the joint EMA/EFSA RONAFA opinion Harmonisation of SPCs of antimicrobial veterinary medicines Antimicrobial resistance (AMR): Presentation on the joint EMA/EFSA RONAFA opinion Harmonisation of SPCs of antimicrobial veterinary medicines EMA Veterinary Medicines Info Day 16-17 March 2017, London

More information

Global Overview on Antibiotic Use Policies in Veterinary Medicine

Global Overview on Antibiotic Use Policies in Veterinary Medicine Global Overview on Antibiotic Use Policies in Veterinary Medicine Dr Shabbir Simjee Global Regulatory & Technical Advisor Microbiology & Antimicrobials Elanco Animal Health Basingstoke, England simjeess@elanco.com

More information

Scientific Discussion post-authorisation update for Rheumocam extension X/007

Scientific Discussion post-authorisation update for Rheumocam extension X/007 5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution

More information

WHO perspective on antimicrobial resistance

WHO perspective on antimicrobial resistance WHO perspective on antimicrobial resistance Bernadette Abela-Ridder, DVM, MSc, PhD Global Foodborne Infections Network (GFN) Coordinator Department of Food Safety and Zoonoses (FOS) 1 Overview of presentation

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL,

More information

UNDERSTANDING SOUTH AFRICA'S CONSUMPTION OF ANTIMICROBIALS

UNDERSTANDING SOUTH AFRICA'S CONSUMPTION OF ANTIMICROBIALS UNDERSTANDING SOUTH AFRICA'S CONSUMPTION OF ANTIMICROBIALS Pharmacy Society of South Africa Conference 2018 Ruth Lancaster Contents 1. Background AMR National Strategic Plan 2. Sources of antimicrobial

More information

Medically Important Antibiotics in Animal Agriculture

Medically Important Antibiotics in Animal Agriculture Medically Important Antibiotics in Animal Agriculture Craig Lewis, DVM MPH Office of the Director Center for Veterinary Medicine Farm Foundation Antimicrobial Stewardship Workshop Davis, California October,

More information

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products

Quality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products Quality of Veterinary Medicinal Products How to ensure the quality of Veterinary Medicinal Products Jean-Pierre Orand Anses/ANMV OIE Collaborating Centre on Veterinary medicinal products Jean-pierre.orand@anses.fr

More information

Units of measurement for animals for the collection of data per animal species: Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet)

Units of measurement for animals for the collection of data per animal species: Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet) for animals for the collection of data per animal species: Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet) Data collection on consumption of veterinary antimicrobials in Europe achievements,

More information

Draft ESVAC Vision and Strategy

Draft ESVAC Vision and Strategy 1 2 3 7 April 2016 EMA/326299/2015 Veterinary Medicines Division 4 5 6 Draft Agreed by the ESVAC network 29 March 2016 Adopted by ESVAC 31 March 2016 Start of public consultation 7 April 2016 End of consultation

More information

Scientific and technical support NOTE of the French Agency for Food, Environmental and Occupational Health & Safety

Scientific and technical support NOTE of the French Agency for Food, Environmental and Occupational Health & Safety The Director General Maisons-Alfort, 18 August 2017 Scientific and technical support NOTE of the French Agency for Food, Environmental and Occupational Health & Safety on "the maximum concentration of

More information

A comparison of antimicrobial usage in human and veterinary medicine in France from 1999 to 2005

A comparison of antimicrobial usage in human and veterinary medicine in France from 1999 to 2005 Journal of Antimicrobial Chemotherapy (2008) 62, 617 625 doi:10.1093/jac/dkn213 Advance Access publication 19 May 2008 A comparison of antimicrobial usage in human and veterinary medicine in France from

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Pro Penstrep Suspension for Injection for Cattle, Sheep and Pigs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:

More information

OIE List of Antimicrobial Agents of Veterinary Importance and OIE Standards and Activities

OIE List of Antimicrobial Agents of Veterinary Importance and OIE Standards and Activities Veterinary Importance and OIE Standards and Activities Consultation meeting with stakeholders - Request from the European Commission for advice on the impact on public and animal health of the use of antibiotics

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle

More information

International Harmonisation in the Field of Pharmacovigilance from an OIE perspective

International Harmonisation in the Field of Pharmacovigilance from an OIE perspective Anses/ANMV OIE Collaborating Centre on Veterinary medicinal products BP 90203-35302 FOUGERES CEDEX, FRANCE elisabeth.begon@anses.fr International Harmonisation in the Field of Pharmacovigilance from an

More information

1 January 2017, It is Coming Preparation for VFD Changes Beginning 1 January 2017

1 January 2017, It is Coming Preparation for VFD Changes Beginning 1 January 2017 1 January 2017, It is Coming Preparation for VFD Changes Beginning 1 January 2017 ASM-00007 1 CHAPTERS Background: Food and Drug Administration (FDA) guidance documents Introduction: Veterinary Feed Directive

More information

CHOICES The magazine of food, farm and resource issues

CHOICES The magazine of food, farm and resource issues CHOICES The magazine of food, farm and resource issues Third Quarter 23 A publication of the American Agricultural Economics Association Lessons from the Danish Ban on Feed- Grade Antibiotics by Dermot

More information

Managing AMR at the Human-Animal Interface. OIE Contributions to the AMR Global Action Plan

Managing AMR at the Human-Animal Interface. OIE Contributions to the AMR Global Action Plan Managing AMR at the Human-Animal Interface OIE Contributions to the AMR Global Action Plan 6th Asia-Pacific Workshop on Multi-Sectoral Collaboration for the Prevention and Control of Zoonoses Dr Susan

More information

Veterinary Feed Directive: What You Need to Know

Veterinary Feed Directive: What You Need to Know Iowa Farm Bureau s Margin Management Webinar Series presents: Veterinary Feed Directive: What You Need to Know Are you prepared for implementation of the Veterinary Feed Directive on January 1, 2017? Introduction:

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET FOR: Cadorex 300 mg/ml solution for injection for cattle, sheep and pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION

More information

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pneumospectin 50 mg/ml +100 mg/ml solution for injection for cattle (calves), sheep, goat, pig,

More information

DANMAP and VetStat. Monitoring resistance and antimicrobial consumption in production animals

DANMAP and VetStat. Monitoring resistance and antimicrobial consumption in production animals DANMAP and VetStat Monitoring resistance and antimicrobial consumption in production animals Flemming Bager Head Division for Risk Assessment and Nutrition Erik Jacobsen Danish Veterinary and Food Administration

More information

SUMMARY OF THE PRODUCT CHARACTERISTICS

SUMMARY OF THE PRODUCT CHARACTERISTICS 1 SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Exflow 10 mg/g powder for use in drinking water for cattle (calves), pigs, chickens, turkeys and ducks Exflow Vet 10

More information

Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate

Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of administration, applicant in the Member States Member State EU/EEA Applicant Name

More information

ANNEXES. to the Proposal. for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

ANNEXES. to the Proposal. for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL EUROPEAN COMMISSION Brussels, XXX SANCO/12328/2013 Rev. 4 ANNEX (POOL/G1/2013/12328/12328R4-EN ANNEX.doc) [ ](2014) XXX draft ANNEXES 1 to 6 ANNEXES to the Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT

More information

Guidance on collection and provision of national data on antimicrobial use by animal species/categories

Guidance on collection and provision of national data on antimicrobial use by animal species/categories 21 February 2018 EMA/489035/2016 Veterinary Medicines Division Guidance on collection and provision of national data on antimicrobial use by animal Draft agreed by European Surveillance of Veterinary Antimicrobial

More information